SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?


To: scaram(o)uche who wrote (2147)5/16/2013 12:24:55 PM
From: nigel bates  Read Replies (1) | Respond to of 2344
 
Just noticed this (FWIW):

"...Cowen & Co. analyst Simos Simeonidis said the latest trial results represent an "unexpected comeback" for L-BLP25 because the results are impressive and they come from a large group of patients. He said Merck KGaA has not announced a decision on the drug but he said he would be surprised it if ended its partnership with Oncothyreon.

Simeonidis rates Oncothyreon shares a "Buy."..."